Entering text into the input field will update the search result below

3 Things In Biotech You Should Learn Today: July 9, 2017

Jul. 09, 2017 8:07 AM ETELTP, RCKT, PFE6 Comments
Zach Hartman profile picture
Zach Hartman


  • Inotek combo trial flops in glaucoma.
  • Elite Pharmaceuticals suffers a setback, too.
  • Pfizer's ODAC meeting for an AML drug poses some ominous challenges.

Welcome to another edition of "3 Things in Biotech You Should Learn Today," a daily series dedicated to helping you sift through the avalanche of pharma news to help solidify your due diligence and find companies you may not be considering.

Let's jump in!

Inotek combo trial flops in glaucoma

The small-cap Inotek (ITEK) has been developing a fixed-dose combination of its own investigational compound, trabodenoson, and the approved prostaglandin F2alpha analog latanoprost for the treatment of glaucoma. Since a recent phase 3 trial of trabodenoson alone failed to yield benefit over placebo, a lot has been riding on the continuing development of the combination.

Unfortunately, it was not meant to be. ITEK announced data from the fixed-dose combination study that showed that the combination failed to significantly improve intraocular pressure compared with latanoprost alone.

The combination was well tolerated, but the lack of efficacy does not spell good things for the further development of trabodenoson.

Looking forward: Like I said, this combo study meant a lot to ITEK, as this is rapidly approaching the end of the line for them. With no other compounds in the pipeline, if they decide to suspend development of their lead compound here, it's difficult to imagine where they'll be able to head next. They maintain about a year's worth of capital at this time, but can they move forward? Shareholders don't seem to think so, as the valuation of the company hovers in microcap limbo.

Elite Pharmaceuticals suffers a setback, too

Elite Pharmaceuticals (OTCQB:ELTP) is a specialist in the development of generic pharmaceuticals, so their main trials are going to be relating to small-scale bioequivalence studies, which comprise a foundational core of their submissions to the FDA.

One of their late-stage agents is an equivalent version of an abuse-deterrent combination of naltrexone and

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.